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The haemolytic-uraemic syndrome (HUS) is the consequence of
one single pathogenic process, leading to either thrombotic-
thrombocytopenic purpura (TTP), or to microangiopathic
haemolytic anemia (MAHA), or to adult HUS (Streiff and Bell,
1993). The aetiology remains unknown, but a number of predis-
posing conditions have been recognized. Cytotoxic drugs have been
identified as playing a causative role in the development of HUS in
cancer patients. Gemcitabine is a newly developed nucleoside
analogue with high activity against pancreatic adenocarcinoma. The
diagnosis of HUS was made in a patient treated with gemcitabine
for metastatic papillary carcinoma for about 10 months. The initial
clinical hint indicating the development of HUS in this patient, the
sudden onset of anaemia and thrombocytopenia, was erroneously
considered to be the result of myelotoxicity exerted by gemcitabine.
The strongly elevated reticulocyte count alone, however, enabled a
diagnosis of a hyperregenerative anaemia due to haemolysis, ruling
out myelotoxicity as the cause of the cytopenia.
CASE REPORT
In December 1994, the clinical diagnosis of a pancreatic carci-
noma of the head of the pancreas was made in the 40-year-old
male patient. He was operated on (Whipple-procedure), and the
final diagnosis was that of a papillary carcinoma. No further
therapy was administered. In August 1996, the patient was seen at
an out-patient department, as an increase in CA 19-9 had been
observed since June 1996. The first recorded elevated value of CA
19-9 was 5440 units l–1 (normal upper limit = 25 U l–1). Abdominal
ultrasound evidenced two intrahepatic lesions (about 2 cm in
diameter) not detected on an examination performed in May 1996.
The diagnosis of metastatic papillary carcinoma was made, and the
patient was offered an experimental therapy with gemcitabine.
Treatment was given as typical weekly infusions over 30 min, with
a dose of 1600 mg day–1 for 3 weeks, followed by 1 week without
gemcitabine. The drug was well tolerated, and no toxicity was
observed. In January 1997, the hepatic lesions had decreased to
about 0.5 cm in diameter (by ultrasound), and CA 19-9 was within
the normal range. In June 1997, with a total dose of 53 400 mg of
gemcitabine, a first episode of thrombocytopenia, 72 000 ml–1, was
observed. Until this date, the platelet count had been between
175000 ml–1 and 685 000 ml–1, with a median of 478 000 ml–1. At
the same time, since August 1996 the LDH had increased from
normal values to 507 U l–1 (upper normal limit of 240 U l–1). The
creatinine, below 1.0 mg dl–1 until this date, increased to 1.3 mg
dl–1. The haemoglobin value, ranging from 10.5 g dl–1 to 14.7 g dl–1
since August 1996, decreased to 8.2 g dl–1. Notably, at this time no
evidence of progressive disease was present. Attributing the
thrombocytopenia and the anaemia to myelotoxicity of gem-
citabine, the therapy was discontinued. At the end of August 1997,
with gemcitabine discontinued for 7 weeks, the laboratory values
had worsened: Plt 101 000 ml–1; Hb 7.2 g dl–1, creatinine 2.9 mg
dl–1, LDH 1190 U l–1, urea 84 mg dl–1, bilirubin 1.7 mg dl–1. On the
day of admission to this hospital, the laboratory values were: urea
124 mg dl–1, creatinine 4.1 mg dl–1, bilirubin 1.3 mg dl–1, LDH
1440 U l–1, plt 100 000 ml–1, Hb 5.6 g dl–1, schistocytes 2.7% of all
RBC, reticulocytes 18% of all RBC. All coagulation parameters
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Correspondence to: S Serkewere within the normal range. Examination of the urine disclosed
no abnormality other than a slight proteinuria (500 mg per 1 l).
The patient was orthopnoic, but auscultation of the lungs disclosed
no abnormality with the exception of bilateral symmetric basal
pleural effusion; the heart sounds were weak, and by ultrasound
a circular pericardiac effusion of about 0.9 cm was detected.
Bilateral ankle oedema (having developed within the last 2 weeks
prior to admission) were evident, and the arterial blood pressure
was 210/115 mmHg as measured on both arms.
Having made the clinical diagnosis of adult HUS in a cancer
patient treated with gemcitabine, therapy was initiated with 2 units
of fresh frozen plasma and 2 units of packed RBC, combined with
the administration of nifedipine and furosemide. As the creatinine
value increased to 5.8 mg dl–1 within 12 h and the orthopnoea
worsened, one single haemodialysis was performed after 12 h
from admission, causing a weight loss of 4.0 kg. After the dialysis,
the first plasmapheresis was performed, with substitution of 4 l of
fresh frozen plasma. Following this plasmapheresis, all laboratory
values improved, and the dyspnoea decreased gradually.
Additional plasmaphereses with substitution of fresh frozen
plasma were performed likewise on days 2, 4, 5 and 6. The arterial
blood pressure normalized within 10 days and nifedipine was
discontinued. Thereafter, plasmaphereses were performed twice
per week until the demission of the patient on day 24. At demis-
sion, creatinine was 2.4 mg dl–1, urea 69 mg dl–1, LDH 280 U l–1,
Hb 12.8 g dl–1, and all other laboratory values had normalized,
including reticulocytes at 2.0% of all RBC and plt of 229 000 ml–1.
From demission on 4 October 1997, the patient was doing well,
but laboratory abnormalities persisted: creatinine 1.8 mg dl–1, urea
49 mg dl–1 (upper normal limit 45 mg dl–1), LDH 285 U l–1, Hb
12.4 g dl–1 (values from 11 November 1997). Early in 1998, CA
19-9 gradually increased to 1965 U l–1, and the hepatic lesions
again gained in size. The patient was given 5-fluorouracil, and
severe diarrhoea developed. After recovery from the diarrhoea, the
patient has again been given gemcitabine. Currently, with another
3000 mg of gemcitabine administered, the patient is doing well
without any signs of recurrence of HUS.
DISCUSSION
It was reported as early as 1962 that HUS occurs associated with
widespread metastatic cancer in patients not receiving
chemotherapy (Brain et al, 1962). In 1980, the first report of a
clinical condition best referred to as HUS in patients treated with
mytomycin-C was published (Gulati et al, 1980). Since this report,
a growing number of chemotherapeutic agents, among those cis-
platinum and bleomycin, have been linked to the development 
of HUS (Nordstrom and Strang, 1993). The etiology of HUS is
unknown, but endothelial damage may lead to extensive formation
of microthrombi in smaller vessels (Matsumae et al, 1996; Groff et
al, 1997). Von Willebrand factor multimers of supranormal size, a
factor predisposing to thrombosis, have been described in patients
with TTP and with HUS (Furlan, 1996; Zeigler et al, 1996).
Although proof is lacking, the thrombocytopenia and the haemo-
lysis are attributed to simple mechanical destruction of these cells
in the microcirculation. The well-vascularized kidney appears to
be the major parenchymatic target for this process of formation of
microthrombi, causing acute renal failure and arterial hypertension
of sudden onset. One feature distinguishing adult HUS from TTP
and from childhood HUS is the development of non-cardiogenic
pulmonary oedema, and focal fibrosing alveolitis with alveolar
septal oedema, capillary congestion and fibrin deposition have
been described (Crocker and Jones, 1983).
The diagnosis of adult HUS is made on the base of the
combination of hyperregenerative thrombocytopenia, haemolytic
anaemia, renal failure with arterial hypertension of sudden onset,
and pulmonary oedema. Neurologic complications, a hallmark for
the diagnosis of TTP, are infrequent.
Therapy of this potentially fatal condition, with a mortality of
25% despite adequate treatment, as reported in one series of 
68 patients treated at one single institution (Conlon et al, 1995),
and with a mortality of 37% in another single-institution series
reporting on 35 patients (Sens et al, 1997), remains controversial,
but plasma infusions and/or plasmapheresis are now recognized as
the modalities with major potential benefit (Sens et al, 1997;
DeWit et al, 1996; Keller et al, 1994).
Gemcitabine has a structure similar to that of cytosine-arabi-
noside, a drug not associated with HUS, and this drug has a well-
documented efficacy against adenocarcinoma of the pancreas,
with minor efficacy against other types of cancer. In one recent
review article (Green, 1996) evaluating toxicity in 790 patients
treated with single-agent gemcitabine, HUS is not mentioned, but
‘a few cases of renal failure of uncertain etiology’ are reported.
Interestingly, although again HUS has not been reported by these
authors, in a second large series of patients participating in phase
II studies (Tonato et al, 1995) it is reported that peripheral oedema
not explainable by renal, hepatic or cardiac dysfunction is
observed in about 10% of patients. In a further series of 360
patients, it is likewise emphasized that the development of periph-
eral oedema was never associated with cardiac, hepatic or renal
failure (Cortes-Funes et al, 1997). It is tempting to speculate that
these oedema might be due to disturbances in the microcirculation,
caused by gemcitabine. In this regard the report of Dobbie et al on
the development of veno-occlusive disease in a patient on gem-
citabine appears to be of particular interest (Dobbie et al, 1998).
In one series of 82 patients on single-agent gemcitabine, it has
been reported that two patients developed acute renal failure 4 and
6 weeks after the last dose of gemcitabine (Anderson et al, 1994).
We were unable to trace any publications reporting on cases of
HUS associated with gemcitabine therapy other than those of
Casper et al (1994) and of Brodowicz et al (1997). Giuseppe
Giaccone has reported on the occasion of the 9th European
Congress for Clinical Oncology (Hamburg, Germany, September
1997) that among 60 patients with advanced NSC-LC treated in a
phase I/II trial with paclitaxel and gemcitabine, one patient
developed haemolytic anaemia, and one patient died owing to
thrombotic-thrombocytopenic purpura (minutes from a satellite
symposium sponsored by Bristol-Myers Squibb Company; host:
Siegfried Seeber). The company marketing gemcitabine states in
an extended data sheet of its product (GEMZAR®) that ‘clinical
findings consistent with HUS were reported in 6 of 2429 patients
(0.25%)’. (Eli Lilly, 1997), probably referring to data-on-file of
patients participating in clinical trials sponsored by this company.
In view of the ill-defined aetio-pathological events leading to
the development of adult HUS in cancer patients, there is no proof
at all that the HUS diagnosed in the patient described by us can be
attributed solely to the therapy with gemcitabine. One alternative
cause for the induction of HUS, the metastatic papillary adeno-
carcinoma itself, is not very probable, as ultrasound examination
disclosed regression of the previously described hepatic lesions
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admission of this patient for HUS. Another alternative cause may
be other drugs: the patient was on propanolol medication for 4
years (continued until today) and prior to each infusion of gem-
citabine he had been given alizaprid (VERGENTAN®). We are
unable, however, to trace any publications on HUS and either of
these two drugs. Thus, gemcitabine is the most probable cause of
HUS in this patient.
The patient described by us had been on gemcitabine for almost
12 months, and a cumulative dose of 53 400 mg had been adminis-
tered. A dose–response relationship is well documented in the
setting of mitomycin-C-induced HUS (Verwey et al, 1987).
Rapid diagnosis of this rare disorder and rapid institution of
adequate therapy might be the reason for the satisfactory outcome
of the episode of HUS in the patient described by us. There is little
doubt, however, that discontinuation of the drug is also mandatory.
We would like to emphasize, however, that in our patient it took
about 8 weeks from the first laboratory hints suggesting HUS
(in retrospect) to the development of the full-blown clinical condi-
tion. During these 8 weeks, the patient had not been treated with
gemcitabine.
We are suggesting, however, despite the low incidence of HUS
associated with gemcitabine, inclusion of additional prescribing
information for this drug. Hyperregenerative haemolytic anaemia
is one hallmark of HUS, and reticulocytes, therefore, are generally
elevated in HUS. Thus, in a patient on gemcitabine therapy who
developes anaemia, a reticulocyte count seems mandatory. In our
patient, the first episode of thrombocytopenia and anaemia was
attributed to myelotoxicity of gemcitabine. This myelotoxicity is
much more frequent than HUS (anaemia: grade I and II in 55%,
grade III and IV in 10%; thrombocytopenia: grade I and II in 37%,
grade III and IV in 10%) (GEMZAR prescribing information, Eli
Lilly). The simple and reliable test for reticulocytes is capable of
differentiating between the hyporegenerative anaemia due to the
myelotoxicity of gemcitabine and the hyperregenerative
haemolytic anaemia due to HUS associated with gemcitabine.
Although a corresponding test is available for ‘reticulated
platelets’ (Kienast and Schmitz, 1990), this test cannot be recom-
mended as a routine clinical-laboratory test. We therefore recom-
mend performing reticulocyte-counting as part of the safety
assessment in each patient on gemcitabine therapy who develops
anaemia or thrombocytopenia.
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